首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1510388

視網膜疾病治療市場規模、佔有率和成長分析：按類型、劑型、分銷管道和地區分類 - 產業預測，2024-2031 年

Retinal Disorder Treatment Market Size, Share, Growth Analysis, By Type(Macular Degeneration, Diabetic Retinopathy, Others), By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年07月05日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年視網膜疾病治療市場規模估值為25億美元，預測期間（2024-2031年）複合年成長率為8.50%，從2023年的27.1億美元增至2031年的52.1億美元，預計還會成長。

視網膜疾病治療市場是醫療保健領域一個充滿活力且快速發展的領域，專注於影響視力的各種視網膜疾病的診斷和管理。影響市場的主要趨勢包括由於人口老化和糖尿病盛行率增加而導致老年黃斑部病變（AMD）、糖尿病視網膜病變和視網膜靜脈阻塞的盛行率老齡化。如果不及時治療，這些疾病可能會導致視力障礙和失明，從而增加對有效治療的需求。重要的進展包括抗 VEGF 藥物、基因療法和幹細胞療法等新療法。 Lucentis和 Eilea 等抗 VEGF 藥物徹底改變了濕性AMD和糖尿病視網膜病變的治療方法，改善了玻璃體內注射的治療效果。基因療法有望改善某些遺傳性視網膜疾病的長期或永久性視力。光同調斷層掃瞄(OCT) 和眼底攝影等視網膜成像技術的進步增強了診斷和監測，從而可以進行早期療育和個人化治療。儘管技術取得了這些進步，但挑戰包括治療成本上升、持續監測的需要以及監管和報銷問題。總而言之，在人口老化和視網膜疾病盛行率上升的背景下，視網膜疾病治療市場的特徵是技術創新和成長機會。希望持續的研究和開發能夠帶來進一步的進步並改善視網膜疾病患者的生活品質。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Novartis（Switzerland）
Roche（Switzerland）
Regeneron Pharmaceuticals（USA）
Genentech（USA）
Allergan（Ireland）
Bausch Health Companies（Canada）
Alimera Sciences（USA）
Ophthotech Corporation（USA）
Spark Therapeutics（USA）
Kodiak Sciences（USA）
Santen Pharmaceutical（Japan）
Bayer AG（Germany）
Regenxbio（USA）
Chengdu Kanghong Pharmaceutical Group（China）
Graybug Vision（USA）
Apellis Pharmaceuticals（USA）
Adverum Biotechnologies（USA）
Clearside Biomedical（USA）
Acucela Inc.（USA）
PanOptica, Inc.（USA）
Opthea Limited（Australia）
Oxurion NV（Belgium）
Kala Pharmaceuticals（USA）
Hemera Biosciences（USA）
Tyrogenex（USA）

簡介目錄

Product Code: SQMIG35I2302

Retinal Disorder Treatment Market size was valued at USD 2.50 Billion in 2022 and is poised to grow from USD 2.71 Billion in 2023 to USD 5.21 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).

The retinal disorder treatment market is a dynamic and rapidly evolving sector within healthcare, focused on diagnosing and managing various vision-affecting retinal conditions. Key trends influencing the market include the rising prevalence of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion due to aging populations and increasing diabetes rates. These conditions can lead to vision impairment or blindness if untreated, driving demand for effective treatments. Significant developments include novel therapies like anti-VEGF drugs, gene therapies, and stem cell therapies. Anti-VEGF drugs, such as Lucentis and Eylea, have revolutionized treatments for wet AMD and diabetic retinopathy, offering improved outcomes through intravitreal injections. Gene therapies promise long-lasting or permanent vision improvement for certain inherited retinal disorders. Advancements in retinal imaging technologies, like optical coherence tomography (OCT) and fundus photography, have enhanced diagnosis and monitoring, enabling earlier intervention and personalized treatments. Despite these innovations, challenges include high treatment costs, the need for ongoing monitoring, and regulatory and reimbursement issues. In conclusion, the retinal disorder treatment market is characterized by innovation and growth opportunities, driven by an aging population and increasing retinal condition prevalence. Continued research and development are likely to bring further advancements, improving the quality of life for those affected by retinal disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Disorder Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Disorder Treatment Market Segmental Analysis

The global retinal disorder treatment market is segmented on the basis of type, dosage form, distribution channel and region. By type, the market is segmented into Macular Degeneration (Dry Macular Degeneration, Wet Macular Degeneration), Diabetic Retinopathy, and Others. By dosage form, the market is segmented into gels, eye solutions, capsules & tablets, eye drops, and ointments. By distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Retinal Disorder Treatment Market

The aging population significantly drives the retinal disorder treatment market, as older individuals are more prone to conditions like age-related macular degeneration (AMD) and diabetic retinopathy. With the elderly population on the rise, the prevalence of these disorders is expected to increase, thereby boosting demand for treatments and therapies. Additionally, technological advancements in ophthalmic treatments, such as anti-VEGF therapies and advanced retinal imaging techniques, have enhanced the diagnosis and management of retinal disorders, offering more effective and less invasive treatment options, leading to better patient outcomes.

Restraints in the Retinal Disorder Treatment Market

High treatment costs for retinal disorders, including expensive anti-VEGF therapies and surgical procedures, significantly restrain the market. These costs can limit access to treatment, especially in regions with limited healthcare resources or inadequate insurance coverage. Additionally, the effective treatment of retinal disorders requires specialized ophthalmologists and retinal surgeons. However, a shortage of these skilled professionals in certain areas further impedes timely access to necessary treatments for patients.

Market Trends of the Retinal Disorder Treatment Market

Significant advancements in retinal imaging and diagnostic technologies, including optical coherence tomography (OCT) and adaptive optics, have greatly improved the early detection and diagnosis of retinal disorders, allowing for timely treatment to prevent further vision loss. The integration of AI and machine learning algorithms into retinal imaging has further enhanced diagnostic accuracy and efficiency, benefiting healthcare providers. Concurrently, the treatment landscape for retinal disorders is evolving with biologic and gene therapy approaches. These innovative treatments target the genetic causes of conditions like retinitis pigmentosa and Leber congenital amaurosis. Gene therapy, particularly, has shown promising clinical trial results and received regulatory approvals for specific conditions, offering long-term benefits by addressing genetic defects and providing hope for patients with previously untreatable disorders.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Regulatory Landscape
Patent Analysis
Pestel Analysis
Key Success Factors
Market Attractiveness Index
Degree of Competition
Top Investment Pockets
Ecosystem Mapping

Retinal Disorder Treatment Market by Type

Market Overview
Macular Degeneration
- Dry Macular Degeneration
- Wet Macular Degeneration
Diabetic Retinopathy
Others

Retinal Disorder Treatment Market by Dosage Form

Market Overview
Gels
Eye Solutions
Capsules & Tablets
Eye Drops
Ointments

Retinal Disorder Treatment Market by Distribution Channel

Market Overview
Hospital
Online
Retail

Retinal Disorder Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alimera Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ophthotech Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spark Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kodiak Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenxbio (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chengdu Kanghong Pharmaceutical Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Graybug Vision (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apellis Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clearside Biomedical (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acucela Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PanOptica, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Opthea Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oxurion NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kala Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hemera Biosciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tyrogenex (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments